Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Parenthetical) (Details) - USD ($) $ in Thousands |
12 Months Ended | |||
---|---|---|---|---|
Dec. 31, 2019 |
Dec. 31, 2018 |
Dec. 31, 2017 |
Sep. 30, 2018 |
|
Revenue Recognition Multiple Deliverable Arrangements [Line Items] | ||||
Revenue from related parties | $ 22,536 | $ 18,966 | $ 44,606 | |
Bristol-Myers Squibb Company ("BMS") | ||||
Revenue Recognition Multiple Deliverable Arrangements [Line Items] | ||||
Revenue from related parties | $ 8,900 | |||
Celgene | ||||
Revenue Recognition Multiple Deliverable Arrangements [Line Items] | ||||
Revenue from related parties | $ 8,900 | |||
Celgene | Minimum | ||||
Revenue Recognition Multiple Deliverable Arrangements [Line Items] | ||||
Ownership percentage | 10.00% |
X | ||||||||||
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|